Field Technologies News

  1. White Paper Examines The Importance Of On-Dose Technologies In The Fight Against Illegal Diversion Of Opioid Medications 5/7/2009
    NanoGuardian™, a division of NanoInk® that delivers brand protection solutions to fight illegal diversion and counterfeiting, announced today that pharmaceutical security expert and co-founder of the Pharmaceutical Security Institute, Dr. John Glover, published a white paper extolling necessary requirements of the Food and Drug Administration (FDA)-proposed Risk Evaluation and Mitigation Strategies (REMS) for opioid products, commonly referred to as pain medications.
  2. BDI Pharma, Inc. To Provide Lundbeck Inc.'s ATryn -- The First Recombinant Antithrombin Approved In The U.S. 5/7/2009
    BDI Pharma, Inc. (BDI) announced today that it is the first specialty biopharmaceutical distributor to be recognized as an official authorized distributor for ATryn® (Antithrombin [Recombinant]).
  3. Ultra-Sanitary Butterfly Valves Ideal For The Control Of Dry Bulk Materials 5/7/2009
    The source for pharmaceutical grade, ultra-sanitary butterfly valves for the control of dry bulk materials. Meeting the stringent requirements of the pharmaceutical, cosmetic, biotech, food and fine chemical industries.
  4. Capsule Fillers Designed For cGMP Production And R&D Environments 5/7/2009
    Designed for cGMP production and R&D environments, the Sejong line of capsule filling machines share the following features that demonstrate superior design, robust construction, low maintenance costs and easy operation.
  5. GlaxoSmithKline To Divest US Rights For Wellbutrin XL To Biovail For $510M 5/7/2009
    GlaxoSmithKline plc (GSK) recently announced that it has entered into an agreement to divest full commercial rights to Wellbutrin XL in the United States to Biovail International Laboratories SRL, a subsidiary of Biovail Corporation, for $510M (£340M).
  6. Hospira Launches Biologics 'Clock' And Web Resource To Raise Awareness Of Potential Biogenerics' Impact 5/7/2009
    Hospira, Inc., the world leader in generic injectable pharmaceuticals, recently launched a clock tracking real-time U.S. prescription sales of costly biologic drugs as part of an informational Web resource highlighting the potential impact of biogenerics – generic versions of biologics – on the U.S. healthcare system.
  7. UCL, Pfizer To Develop Pioneering Stem Cell Sight Therapies 4/28/2009
    UCL has entered into a collaboration with the biopharmaceutical group Pfizer, negotiated by UCL Business, to advance development of stem cell-based therapies for age-related macular degeneration (AMD).
  8. Rwanda Becomes First Developing Nation To Introduce Vaccine For World's Leading Infectious Child Killer 4/28/2009
    International leaders in global health will join Rwandan government officials at a press conference in the coming days in Kigali to announce the first national immunisation programme against pneumococcal disease in a developing country.
  9. Phase 3 Trial Of Nexavar In Chemotherapy-Naive Patients With Advanced Melanoma Does Not Meet Primary Endpoint 4/28/2009
    Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. recently announced that a Phase 3 trial evaluating Nexavar (sorafenib) tablets in patients with unresectable stage III or stage IV melanoma was stopped early following a planned interim analysis by the independent Data Monitoring Committee (DMC).
  10. China Breaks Ground On Largest Comprehensive Stem Cell Storage And Processing Facility 4/23/2009
    Jiangsu government’s China Medical City (CMC) and Shenzhen Beike Biotechnology Co. Ltd. (http://www.beikebiotech.com) broke ground on the 20,000 square-meter Stem Cell Regenerative Medicine Industrial Project of National Bio-Industry Base (NBPD).